

Updated: 09/2023 DMMA Approved: 09/2023

Request for Prior Authorization for Cough and Cold Medications for Children Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Opioid Cough and Cold Medications for Children will be reviewed under policy CP.206.216-MD-DE Age Edits. All request for Non-Opioid Cough and Cold Medications for Children Less than 4 Years require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Cough and Cold Medications for Children Prior Authorization Criteria:

For all requests for Cough and Cold Medications for Children Less than 4 Years all of the following criteria must be met:

- Member must have a history of trial and failure with ONE of the following treatments:
 - o Cool mist humidifier/vaporizer
 - Saline nose drops or spray
 - Nasal Aspirator
- Medication must be packaged and labeled for pediatric use
- A review of active authorizations will be completed to ensure no duplication of active ingredients
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 10 days
- Reauthorization criteria
 - A chart documented evaluation for other diagnoses (such as allergies, bronchitis, pneumonia) if symptoms last longer than 10 days
- **Reauthorization Duration of Approval:** 10 days

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.



Updated: 09/2023 DMMA Approved: 09/2023

COUGH AND COLD MEDICATIONS FOR CHILDREN PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart

			Services. FAX: (855) 476-4158	or chart
	ed, you may call to speak to			
PHO	NE: (844) 325-6251 Monday	y through Friday 8:0	00am to 7:00pm	
	PROVIDER II	NFORMATION		
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			NPI:	
Provider Specialty:			Office Contact:	
Office Address:			Office Phone:	
		Office F	ax:	
	MEMBER IN	FORMATION		
Member Name:	DOB:			
Health Options ID:	Membe		pounds or	kg
REQUESTED DRUG INFORMATION				
Medication:	Strength:			
Frequency:		Duration:		
Is the member currently receiving i				
Is this medication being used for a	chronic or long-term conditi	ion for which the me	edication may be necessary for	he life of
the patient? Yes No				
Billing Information				
This medication will be billed: at a pharmacy OR medically (if medically please provide a JCODE:				
Place of Service: Hospital Provider's office Member's home Other				
Place of Service Information				
Name:	Trace of Scr vi	NPI:		
Address:		Phone:		
Tiddress.		T none:		
MEDICAL HISTORY (Complete for ALL requests)				
Is the medication packaged and labeled for pediatric use? Yes No				
Will the member be using any other medications that will result in a duplicate therapy? \(\subseteq \text{ Yes} \subseteq \subseteq \text{ No} \)				
Has the patient tried and failed the following treatments?				
Humidifier or vaporizer: Yes [
Saline nasal drops: Yes No				
Nasal aspirator: Yes No				
CURRENT or PREVIOUS THERAPY				
Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & W	ny/Current)
REAUTHORIZATION				
Please provide the associated diagram	nosis if therapy is required for	or greater than 10 da	ys:	
SUPPORTING INFORMATION or CLINICAL RATIONALE				
5011		IN OF CLINICAL I	RATIONALL	
Prescribing Provide	er Signature		Date	
Trescribing 110viu	SI-Signature		Date	



Updated: 09/2023 DMMA Approved: 09/2023